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Abstract
Acquired somatic mutations are responsible for approximately 90%
of breast tumours. However, only one somatic aberration,
amplification of the HER2 locus, is currently used to define a
clinical subtype, one that accounts for approximately 10% to 15%
of breast tumours. In recent years, a number of mutational profiling
studies have attempted to further identify clinically relevant
mutations. While these studies have confirmed the oncogenic or
tumour suppressor role of many known suspects, they have
exposed complexity as a main feature of the breast cancer
mutational landscape (the ‘muta-ome’). The two defining features
of this complexity are (a) a surprising richness of low-frequency
mutants contrasting with the relative rarity of high-frequency events
and (b) the relatively large number of somatic genomic aberrations
(approximately 20 to 50) driving an average tumour. Structural
features of this complex landscape have begun to emerge from
follow-up studies that have tackled the complexity by integrating
the spectrum of genomic mutations with a variety of comple-
mentary biological knowledge databases. Among these structural
features are the growing links between somatic gene disruptions
and those conferring breast cancer risk, mutually exclusive
coexistence and synergistic mutational patterns, and a clearly non-
random distribution of mutations implicating specific molecular
pathways in breast tumour initiation and progression. Recognising
that a shift from a gene-centric to a pathway-centric approach is
necessary, we envisage that further progress in identifying clinically
relevant genomic aberration patterns and associated breast cancer
subtypes will require not only multi-dimensional integrative
analyses that combine mutational and functional profiles, but also
larger profiling studies that use second- and third-generation
sequencing technologies in order to fill out the important gaps in
the current mutational landscape.
The copy-number ‘muta-ome’
The most prominent feature in the breast cancer copy-
number muta-ome is amplification of the HER2 locus, present
in about 10% to 15% of all breast tumours. It is remarkable
that since the discovery of this amplification no further
ERBB2-like oncogene has been conclusively identified.
Although two recent large-scale (145 and 171 tumours)
genome-wide profiling studies combining high-resolution
copy-number and matched gene expression data have
confirmed candidate oncogenes in well-known regions of
recurrent amplification (notably, 8p12, 8q24, 11q13-14,
17q21-24, and 20q13), none of these appears to be as
frequently amplified as ERBB2 and they rarely exhibit
amplification profiles that clearly point at a specific genomic
location or target [1,2]. Instead, the amplification profiles are
complex and multi-modal, suggesting that multiple targets
may coexist within these regions. This identification problem
is compounded by the fact that a relatively high proportion of
variation at the gene expression level (approximately 20%) is
driven by copy-number changes; thus, focusing on regions of
expression bias that are driven by underlying amplifications
(so-called ‘hotspots’) still leaves an unmanageably large
number of targets. Nevertheless, by focusing within these
hotspots on genes that are also druggable, Chin and
colleagues [1] prioritised a smaller set of eight targets,
FGFR1, IKBKB, PROSC, ADAM9, FNTA, ACACA, PNMT,
and NR1D1, including ERBB2. Confirming the robustness of
these findings, all of these were also found to reside in
amplification hotspots in an independent breast cancer
cohort [2] (A.E. Teschendorff and C. Caldas, unpublished
data). In spite of this agreement, the two studies were
discordant when hotspots were associated with clinical
outcome, mirroring the disagreements of initial gene
expression studies. Thus, whereas in [1] associations with
survival and recurrence were restricted to the amplicons on
8p11-12 and 17q11-12, in [2] outcome-associated
amplicons were found on 8q22.3, 8q24.3, 8q24.11-13, and
11q14. As explained in [2], this disagreement is most likely
due to substantial differences in the clinical characteristics of
the two cohorts, yet the lessons learned from mRNA
expression microarray studies also suggest that larger studies
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may help to resolve such discrepancies. In fact, given the
increased complexity of genomic breast cancer profiles
relative to mRNA profiles, much larger sample sizes
(approximately 500 to 1,000) might be needed before
substantial overlap between prognostic copy-number
signatures is found. In addition, given that among copy-
number aberrations it is high-level amplifications that seem to
carry most of the prognostic significance [1,2], the
development of a future prognostic copy-number signature,
similar to the expression signatures currently being tested in
clinical trials, would benefit from higher-resolution studies
such as those using single-nucleotide polymorphism (SNP)
arrays or next-generation sequencing technologies, as these
have the capability to detect more focal (that is, less than 20
to 200 Kb) amplifications and homozygous deletions (HDs).
Indeed, a recent high-resolution 317,503 to 555,351 SNP
array study of 45 breast tumours was able to detect a larger
repertoire of copy-number amplifications and HDs, some
smaller than 250 Kb [3]. Thus, in addition to identifying focal
aberrations encompassing known oncogenes (CCND1,
CCNE1, and FGFR2) and tumour suppressors (CDKN2A
and  PTEN), they uncovered a number of other important
genes with likely oncogenic or tumour suppressor roles
(PCDH8, MRE11A, and HOXA3) [3]. The higher-resolution
SNP array also allowed Leary and colleagues [3] to estimate
an average number of 18 copy-number aberrations (7 HDs
and 11 high-level amplifications) that were altered
significantly above the background mutation rate, implicating
about 24 genes that are driving tumour progression.
Larger-scale profiling studies are also needed in order to
more fully characterise the genomic landscape of breast
cancer. So far, four main genomic subtypes that roughly
correlate with the well-known intrinsic subtypes defined from
gene expression studies have been identified [1,2].
Specifically, one subtype (called ‘simple’) consisted almost
entirely of estrogen receptor-positive (ER+)/luminal-A tumours
and is characterised mainly by a relatively simple genomic
profile defined by a gain of 1q and 16p and a simultaneous
loss of 16q. Another genomic subtype (‘simple amplifier’) was
characterised mainly, but not exclusively, by amplifications on
11q13-14 and 17q11-13 and mapped roughly to the
ER+/luminal-A and ER–/HER2+ expression subtypes, respec-
tively. Thus, amplifications on 11q13-14 and 17q11-13
occurred in a largely mutually exclusive fashion, suggesting
that these tumours are using distinct oncogenic mechanisms.
A third genomic subtype (‘complex amplifier’) showed the
highest degree of genomic instability (GI) and complex
rearrangements, including frequent amplifications at the 8q24
and 8p12 loci. This genomic subtype is that of worst
prognosis, consisting mainly of ER–/basal and ER+/luminal-B
tumours. A fourth genomic subtype consisted mainly of
ER–/basal tumours but was characterised, surprisingly, by a
low GI profile (‘flat’) [2]. It is doubtful, however, whether such
classifications will have much relevance as it is likely that the
clinically relevant phenotypes are determined by specific
combinations of different types of somatic mutations. Thus, to
identify breast cancer genomic subtypes that are more
relevant, we envisage that it will be necessary to derive and
analyse multi-dimensional mutational profiles.
The point ‘muta-ome’
Two recent landmark sequencing studies [4,5] have also
revealed the remarkable complexity of the point mutational
landscape of breast cancer. In addition to the high-frequency
somatic point mutations in TP53 (53%), PIK3CA (26%), and
CDH1 (21%) (the so-called gene ‘mountains’), these studies
have confirmed a surprisingly larger number of other genes that
also appear to be more frequently mutated than what can be
accounted for by chance, albeit at much lower frequencies
than TP53 or PIK3CA. Specifically, for the 11 breast tumours
considered in the discovery screen of [5], a total of 1,137
RefSeq genes contained a somatic mutation and 167 of these
were also validated in an independent screen of 24 samples.
When a number of different estimation procedures for
passenger mutation rates were used, it was found that
approximately 120 genes were more frequently mutated than
the passenger rate, suggesting that these genes are more likely
to carry driver mutations (so-called CAN genes). This translates
into an average of 101 non-synonymous somatic mutations in
RefSeq genes per breast tumour, and approximately 14 of
these are thought to be located in CAN genes [5]. It could be
argued that this is a gross overestimate due to the highly
tumourigenic nature of the breast samples considered (all were
ER– cell lines mostly representing metastases); however, it is
also plausible that it would increase as larger-scale sequencing
studies get completed. Combining the published estimate with
the average number of 24 driver amplifications/HDs affecting
any given breast tumour and assuming mutual exclusivity of
mutation type, this would implicate an average of approximately
40 CAN genes in any given tumour.
Given that estimates of passenger mutation rates are only
approximate and that a high mutation rate may reflect
mechanisms that are only indirectly related to tumour genesis
or progression, it could be expected that many of the
identified CAN genes are false-positives. Nevertheless,
several of the CAN genes identified in [4,5] (notably, IKBKB,
IKBKA,  CHD5,  STK11, STK6, and  BRAF) have been
independently implicated in breast or other tumours, whereas
other genes (for example, ATM  and  FGFR2) have been
associated with germline mutations and an increased risk of
breast cancer. Moreover, in an independent bioinformatics
study, several breast cancer CAN genes (GAB1, NLE1, and
CNTN6) were rediscovered as members of protein
interaction subnetworks with combined expression levels that
correlated with clinical outcome [6], consistent with the idea
that mutations in these genes are disrupting important
signalling pathways and thus fuelling malignant progression.
Taken together, these observations provide strong support
for the direct causal role of the identified CAN genes in tumour
progression and, for some, probably tumourigenesis also.Massively parallel sequencing: a fusion
‘muta-ome’?
The emerging pattern of a few highly prevalent CAN genes
(‘mountains’) with a much larger number of low-frequency
events (‘hills’) parallels the aberration landscape pattern
observed at the copy-number level. Thus, a question posed
by these studies is whether the relative scarcity of cancer
gene ‘mountains’ is a genuine feature of the cancer muta-ome
or whether it merely reflects the inability of the technology to
detect further high-frequency mutations. While the latter
scenario seems to be highly unlikely in the case of point
mutations [5], more focal (=20 to 50 kB) amplifications and
deletions will be discovered using higher-resolution SNP
arrays and massively parallel sequencing, as already
demonstrated with SNP arrays by Leary and colleagues [3],
yet it also seems unlikely that these will constitute novel gene
‘mountains’. Another possibility is that the missing high-
frequency events involve other types of genomic rearrange-
ments such as balanced translocations or inversions, which
are not detectable using copy-number analysis but which may
be discovered using massively parallel paired-end sequen-
cing or transcriptome sequencing, as illustrated recently in
lung cancer [7], prostate cancer [8], and breast cancer [9,10]
cell lines. Using a combined strategy of short- and long-read
transcriptomic sequencing of a metastatic prostate cancer
cell line, Maher and colleagues [8] identified a variety of
mechanistically different and novel gene fusions, including a
novel read-through gene fusion chimaera SLC45A3-ELK4,
which interestingly was also found to be aberrantly expressed
in 7 out of 20 (35%) metastatic prostate cancer cell lines, 6
of which were negative for ETS gene fusions. Similarly, long-
read transcriptomic sequencing of a breast cancer cell line
(HCC1954) identified not fewer than seven chimaeric
transcripts arising mostly from intragenic to intergenic gene
fusion events leading to protein truncation. Notably, among
the seven rearrangements, one, t(4;11)(q32;q21), causes
truncation of the DNA-binding domain of MRE11A, a
candidate tumour suppressor involved in DNA damage repair,
whereas two other fusions, t(5;8)(q35.3;q24.21) and
t(5;8)(p15.33;q24.21), implicate the known cancer genes
NSD1 and  PVT1 and the 8q24.21 breast cancer
susceptibility region. Although these findings are very
encouraging, large-scale sequencing studies will be needed
to evaluate the prevalence of these genomic fusion
aberrations in breast cancer. If these studies were to confirm
that specific inter- and intra-chromosomal gene fusions are
highly frequent events in breast cancer (as already
demonstrated in prostate cancer), it would vindicate the long-
held belief that this type of rearrangement constitutes the
most prevalent category of somatic aberrations in all tumours.
Tackling the complexity: structural features of
the ‘muta-ome’
The broad picture emerging from the large-scale low-
resolution array-based comparative genomic hybridisation
studies [1,2] and the smaller-scale higher-resolution sequen-
cing studies [5,9,10] is that of a highly complex genomic
landscape, not only in terms of the sheer numbers of genes
that may be directly implicated, but also in terms of the
different types and flavours of genomic rearrangements that
seem to be causally involved. Clearly, building a vast cata-
logue of somatic mutations in breast cancer [11] constitutes
only the first step on the long road to identifying novel drug
targets and developing therapies that are more effective.
Although the catalogue is still incomplete, it is comprehensive
enough that various structural features are starting to emerge.
First, point mutations that are activating or inactivating often
occur in genes that are also commonly amplified or deleted
[3,12]. This observation is important for it identifies genes
that are disrupted by multiple, and possibly equivalent,
mechanisms and that therefore are more likely to drive tumour
progression. Thus, it may be possible to categorise all
somatic mutations into activating or inactivating aberrations
and to carry this simplified picture forward when analysing the
systems-level implications of these aberrations. A similar
approach was taken by Leary and colleagues [3], who
combined the point and copy-number mutomes to identify
pathways targeted for disruption.
A second structural feature to emerge has been the mutual
exclusivity pattern of mutations [13], often involving genes in a
common pathway or genes exhibiting high sequence similarity
[14], as well as cooperative or synergistic interactions, often
involving physically interacting proteins such as the SMAD2
and SMAD3 receptors in colorectal cancer [4]. In the case of
breast cancer, there are some clear mutual exclusivity patterns
emerging (for example, those of PIK3CA and TP53 mutations;
A.E. Teschendorff and C. Caldas, unpublished data) and
independent hints of further patterns such as those of
PIK3CA and RAS [13,15] as well as hints of cooperation or
coexistence such as that involving HER2 amplification and
PTEN loss (including loss of PTEN expression) [15]. Although
in most of these studies sample sizes are still too small for the
results to be conclusive, the strong mutual exclusivity and
cooperative patterns observed in, for example, a sequencing
study of 188 lung tumours [12] suggest that similar mutational
patterns will be seen in breast cancer.
Finally, a third feature to emerge is the evidently non-random
distribution of mutations and affected genes in relation to
specific protein domains, gene functions, and molecular path-
ways. In the case of somatic mutations, a strong association
with spectric repeat and fibronectin domains, GTPase
activation, extracellular matrix, and cell-cell adhesion as well
as calcium ion-binding functions was observed [14,16]. This
reinforces the crucial role that cytoskeletal, including cell-cell
adhesion, dysregulation plays in malignant progression of
breast cancer, although it remains to be seen how this may
depend on the subtype and stage of the specific tumours
studied [14,16]. In the context of pathways, somatic
mutations were found to be enriched in many pathways
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signalling, cell-cycle checkpoint (G1-S), BRCA1/2 (breast
cancer 1/2, early onset)-related DNA repair, and phospha-
tidylinositol 3 kinase (PIK3) and v-akt murine thymoma viral
oncogene homolog 1 (AKT) and transforming growth factor-
beta (TGF-β) signalling [14,16]. In an integrative strategy,
incorporating both point and copy-number aberrations in the
enrichment analysis, Leary and colleagues [3] identified
further important signalling pathways such as those of Notch,
epidermal growth factor receptor (EGFR), fibroblast growth
factor (FGF), and v-erb-b2 erythroblastic leukemia viral
oncogene homolog 2 (ERBB2). Thus, these results should
help to direct increasingly focused efforts that aim to develop
therapies tailored to restoring these disrupted pathways. The
study of Lin and colleagues [14] also illustrates nicely the
added insights gained by adopting a more systems-level
approach, mapping mutations onto well-curated protein
interaction networks in order to identify subnetworks more
prone to disruption. Specifically, they were able to show that
genes targeted by point mutations are more prone to occupy
hubs in the corresponding protein interaction networks as
opposed to genes that are not. Interestingly, of the 83
somatically mutated proteins in breast cancer [17], over half
(59) were shown to be part of a large interaction cluster
involving  TP53,  BRCA1,  PIK3R1, and NFKB. Thus, a full
interpretation and understanding of how the approximately 30
to 40 CAN genes driving a given tumour cooperate to disrupt
important signalling pathways, that themselves exhibit
significant cross-talk, will undoubtedly benefit from network-
based approaches that try to give meaning to the aberrations
in the context of the whole interaction network. Some further
insights in this direction were recently offered by Taylor and
colleagues [18], who showed that tumours are preferentially
disrupted at ‘intermodular’ hubs, representing proteins that
mediate signals between different cellular functions.
The structural features of the complex muta-ome are only
beginning to emerge, and full elucidation of these features
will be crucial for translating the vast and growing catalogue
of somatic mutations into improvements for therapy and
eventual cures. Given the heterogeneity of breast cancer,
accomplishing this goal will require upscaling the current
Genome Atlas Research Project [19] to generate multi-
dimensional high-resolution mutational and functional profiles
of hundreds if not thousands of tumours.
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